Roche Holding AG (RO)

374.00
+4.40(+1.19%)
  • Volume:
    98,628
  • Bid/Ask:
    373.80/374.00
  • Day's Range:
    365.00 - 374.00

RO Overview

Prev. Close
369.6
Day's Range
365-374
Revenue
58.32B
Open
366.8
52 wk Range
292.4-374.6
EPS
16.52
Volume
98,628
Market Cap
319.07B
Dividend (Yield)
9.10
(2.43%)
Average Vol. (3m)
73,359
P/E Ratio
21.08
Beta
0.88
1-Year Change
8.2%
Shares Outstanding
853,125,950
Next Earnings Date
Jul 22, 2021
What is your sentiment on Roche Holding AG?
or
Market is currently closed. Voting is open during market hours.

Roche Holding AG News

Roche Holding AG Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy

Roche Holding AG Company Profile

Roche Holding AG Company Profile

Industry
Major Drugs
Employees
101465

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Read More
  • A large pharmaceutical company, by the name of R. , is pushing down the value of the Spanish company's Pharmamar share price through the funds Consonance Capital and Great Point Partners, so that the biotech company accepts its offer of more than 4500 million dollars.According to this pharma, Pharmamar's products have a great future in oncology and virology, and would be fully engaged in its search for new drugs.
    0
    • 13.11.2020. CHMP recommends EU approval of Roche’s Xofluza® (baloxavir marboxil) for the treatment of influenza. This CHMP recommendation brings patients with influenza one step closer to potentially benefiting from Xofluza’s oral one-dose regimen, setting adults and adolescents on the path to feeling better sooner compared to placebo,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We believe that access to effective antivirals for influenza, and particularly their use in the prophylactic setting, could help reduce the strain of the COVID-19 pandemic on healthcare systems in Europe.
      0
      • Just like Biolidics. they get approval for Covid19 tests kits in USA
        0
        • i dont know
          0
          • is the historical price adjusted for stock splits?
            0
            • i dont know
              0
          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.